Deal Pathway
We travel to 12+ conferences a year, meet the pharma BD teams, and put your asset directly in front of the ones who are actively looking. Success-based — we earn when you do.
Start a ConversationHow It Works
We analyse your asset and build a curated, tiered investor and pharma partner target list with clear rationale for each.
We refine your deck, email templates, and non-confidential overview — tailored for each audience segment.
We reach out on your behalf with personalized, evidence-backed messages. Not volume spray — curated engagement.
Before BIO International, BioChina, or any key conference — we agree on priority targets, set up meetings, and prep you. No more wasted trips.
Concise dossiers for each meeting. Structured follow-up notes and next steps so nothing falls through.
As discussions get serious — deal benchmarking, term sheet clarification, and narrative support for boards.
Fee Model
We do not sell meetings or charge per introduction. Our fees are structured to align our success with yours.
We sell analysis, prioritization, positioning, and representation — not access to a list you could get from a conference badge scan.
Included in Deal Pathway. Asset analysis, curated target list (20-40 names), tiered by fit and rationale.
Proactive introductions, deck refinement, meeting prep, conference BD packages. Fixed add-on fee.
A percentage of capital raised or deal value when a transaction closes through our introductions.
We use our global network and intelligence — conference lists, investor databases, and AI-powered market research — to identify and prioritize the most relevant investors and partners for your asset.
You receive our thinking, not raw data. Curated target lists, strategic positioning, and guided access to the right conversations.
Tell us about your lead asset and objectives. We will come back with an honest view of whether we can help and how.
Apply Now